Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 75

Results For "SEC"

3011 News Found

Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001
News | July 11, 2025

Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001

IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China


Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy
Supply Chain | July 11, 2025

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy

Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders


Bayer submits EU application for Gadoquatrane MRI contrast agent
News | July 11, 2025

Bayer submits EU application for Gadoquatrane MRI contrast agent

It is intended for contrast enhancement in MRI scans


Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products
News | July 11, 2025

Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products

Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content


Syngene announces 3rd year of STEM scholarship for women with RICH
News | July 11, 2025

Syngene announces 3rd year of STEM scholarship for women with RICH

This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background


Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause
Drug Approval | July 11, 2025

Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause

The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials


Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
News | July 11, 2025

Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting

Xtandi is approved in over 80 countries, including the U.S., EU, and Japan


IMCD opens life science laboratory hub in Shanghai
News | July 09, 2025

IMCD opens life science laboratory hub in Shanghai

The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms


Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Biotech | July 08, 2025

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need


AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Clinical Trials | July 08, 2025

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments